|
| 37878154 | Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer. | Breast Cancer Res Treat | 2024 |
| 37889120 | Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer. | Clin Cancer Res | 2024 |
| 36351835 | Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen Metabolism. | Drug Metab Dispos | 2023 |
| 37488395 | ASO Author Reflections: Low Estrogen Receptor (ER) Expression Breast Cancer Behaves More like ER Negative Disease and Influences Management. | Ann Surg Oncol | 2023 |
| 37556775 | Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. | J Clin Oncol | 2023 |
| 38072514 | Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. | Ann Oncol | 2023 |
| 38072513 | Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. | Ann Oncol | 2023 |
| 37589839 | Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes. | Breast Cancer Res Treat | 2023 |
| 37516725 | ASO Visual Abstract: Clinical Behavior, Management, and Treatment Response of Estrogen Receptor-Low (1-10%) Breast Cancer. | Ann Surg Oncol | 2023 |
| 37460743 | Clinical Behavior, Management, and Treatment Response of Estrogen Receptor Low (1-10%) Breast Cancer. | Ann Surg Oncol | 2023 |
| 36993608 | Clinical Outcomes and Prognostic Factors in Triple-Negative Invasive Lobular Carcinoma of the Breast. | Res Sq | 2023 |
| 37253507 | Advances in systemic therapies for triple negative breast cancer. | BMJ | 2023 |
| 37382948 | Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review. | JAMA Oncol | 2023 |
| 37210429 | Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast. | Breast Cancer Res Treat | 2023 |
| 37308117 | NCCN Guidelines® Insights: Breast Cancer, Version 4.2023. | J Natl Compr Canc Netw | 2023 |
| 37072398 | Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. | Nat Commun | 2023 |
| 37004493 | Development and validation of a liquid chromatography-mass spectrometry assay for quantification of Z- and E- isomers of endoxifen and its metabolites in plasma from women with estrogen receptor positive breast cancer. | J Chromatogr B Analyt Technol Biomed Life Sci | 2023 |
| 37226243 | Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors. | Breast Cancer Res | 2023 |
| 37260292 | Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer. | Clin Cancer Res | 2023 |
| 37195235 | A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. | Clin Cancer Res | 2023 |
| 36926316 | Disruption of estrogen receptor beta's DNA binding domain impairs its tumor suppressive effects in triple negative breast cancer. | Front Med (Lausanne) | 2023 |
| 36521078 | Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. | J Clin Oncol | 2023 |
| 36469363 | Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor-Positive Breast Cancer. | Cancer Res | 2023 |
| 36735254 | Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010. | JAMA Netw Open | 2023 |
| 36635351 | PDJ amplicon in triple negative breast cancer. | Sci Rep | 2023 |
| 36493792 | Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. | Lancet Oncol | 2023 |
| 36756142 | Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer. | Ther Adv Med Oncol | 2023 |
| 36892847 | Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 33160859 | MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. | Acad Radiol | 2022 |
| 35734391 | Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. | NAR Cancer | 2022 |
| 35569077 | Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67. | Ann Surg Oncol | 2022 |
| 35358345 | Population Pharmacokinetics of Z-Endoxifen in Patients With Advanced Solid Tumors. | J Clin Pharmacol | 2022 |
| 35714673 | Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 35776260 | ASO Visual Abstract: Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer-Effects of Age and Tumor Ki67. | Ann Surg Oncol | 2022 |
| 36458203 | Oncolytic Urabe mumps virus: A promising virotherapy for triple-negative breast cancer. | Mol Ther Oncolytics | 2022 |
| 36045271 | Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study. | Breast Cancer Res Treat | 2022 |
| 35871670 | ASO Visual Abstract: Nodal Pathologic Complete Response Rates in Luminal Breast Cancer Vary by Genomic Risk. | Ann Surg Oncol | 2022 |
| 36092362 | Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an <i>H</i> <i>.</i> <i>pylori</i> immunostimulatory bacterial transgene. | Mol Ther Methods Clin Dev | 2022 |
| 36077757 | Identification of Src Family Kinases as Potential Therapeutic Targets for Chemotherapy-Resistant Triple Negative Breast Cancer. | Cancers (Basel) | 2022 |
| 35876925 | Nodal Pathologic Complete Response Rates in Luminal Breast Cancer Vary by Genomic Risk. | Ann Surg Oncol | 2022 |
| 35046057 | The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. | Clin Cancer Res | 2022 |
| 35223458 | Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study. | Front Oncol | 2022 |
| 35012799 | Corrigendum to "Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria": [Annals of Oncology 32 (2021) 950-953]. | Ann Oncol | 2022 |
| 35177654 | Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer. | NPJ Breast Cancer | 2022 |
| 35177334 | Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG). | Genet Med | 2022 |
| 35331649 | Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study. | Genet Med | 2022 |
| 34995105 | Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). | J Clin Oncol | 2022 |
| 34902335 | Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. | Lancet Oncol | 2022 |
| 35082299 | Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities. | Nat Commun | 2022 |
| 34667110 | Anastrozole Regulates Fatty Acid Synthase in Breast Cancer. | Mol Cancer Ther | 2022 |